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Introduction
Because of the progress made in early detection and surgical treatment of the primary tumor, mortality in cancer patients is increasingly linked to metastatic disease. Bone is the second most common site of metastasis 1 and the frequency of bone metastases at autopsy of cancer patients varies between 60 and 85%, depending on the cancer type [2] [3] [4] .
Clinical and experimental observations indicate that the hematopoietic marrow, rather than the bone tissue, is the initial site of cancer cell seeding 5 . Indeed, small clusters of cancer cells (= micrometastases) can be detected in a vast proportion of the bone marrow aspirates of subjects affected by a variety of epithelial cancers with no radiological or scintigraphic evidence of bone metastasis at the time of diagnosis and/or surgery of the primary tumor 6, 7 . Micrometastases represent the pathophysiological basis of minimal residual disease 8, 9 (MRD) that will eventually lead to cancer relapse as overt metastases. However, they cannot be detected by conventional staging methods and are poorly influenced by current treatment [8] [9] [10] . Hence, there is a need for alternative therapeutic strategies that should be tested in experimental models able to mimic micrometastatic spread.
Injection of cancer cell lines into the left cardiac ventricle of immunodeficient (nu/nu)
mice is a widely used animal model of bone/bone marrow metastasis 11, 12 . This experimental setting closely resembles the clinical situation of MRD after removal of the primary tumor. However, detection of bone metastasis by radiography 13 makes it not an ideal model of MRD. In fact, radiologically evident osteolytic/osteosclerotic metastases are a late and macroscopic event in the evolution of metastatic bone disease. Thus, the model lacks the sensitivity that would be necessary to dissect the initial processes, such as the "angiogenic switch" 14 , essential for tumor progression 15 . Furthermore, the radiological detection of osteolytic and/or osteosclerotic metastases is an indirect measure of the tumor burden.
Only a parallel histomorphometric analysis allows the distinction between a therapeutic effect exerted directly on tumor cells or indirectly through inhibition of bone resorption.
Therefore, more sensitive methods to detect and monitor directly metastatic growth in bone marrow/bone of whole animals need to be developed.
Expression in vivo of reporter genes encoding bioluminescent 16 or fluorescent 17 proteins can be detected externally by sensitive detection systems. Cancer cell lines permanently transfected either with the firefly luciferase (Luc) or the green fluorescent protein (GFP) have been used to monitor in living mice local tumor growth 18 and development of metastasis to different organs 17 .
We investigated the possibility to apply an equivalent bioluminescent imaging method to visualize in vivo the development of bone marrow/bone metastases after injection of luciferase-transfected MDA-MB-231 cells, a human mammary carcinoma cell line 19 , into the left cardiac ventricle of immunodeficient (nu/nu) mice.
Here we demonstrate that whole-body bioluminescent reporter imaging (BLI) effectively allows sensitive localization and growth monitoring of minimal metastatic deposits in the bone marrow at a stage largely preceding tumor-induced osteolysis.
Materials and Methods

Animals
Female BALB/c nu/nu mice were purchased from Iffa Credo (L'Arbresle, France). 
Cell lines
The human mammary carcinoma cell line MDA-MB-231 (MDA-231) was obtained from the Determination of the lowest cell number detectable in bone
Intraosseous implantation of cancer cells
The knee articulation was forced in a flexed position and a 27-gauge needle was inserted through the patellar tendon and guided toward the articular surface of the femur with gentle drilling motion until the bone cortex was perforated. 22 
Bioluminescent reporter imaging (BLI)
An imaging system essentially equivalent to that described by Contag and co-workers and processed by an image analysis software (Openlab™, Improvision, Coventry, UK).
For the detection of luciferase expressing cells, mice were anaesthetized as described above, but using half the doses of each sedative. Thirty μl of a 250 mM aqueous solution of luciferin (D-Luciferin Na salt; Molecular Probes, Leiden, Netherlands) were injected i.p. 15 minutes before beginning photon recording. Mice were placed in the light-tight chamber and a grey-scale image of the animal was first recorded with dimmed light. Photon emission was then integrated over a period of 5 minutes and recorded as pseudo-color images. For co-localization of the bioluminescent photon emission on the animal body, grey-scale and pseudo-color images were merged by using the Openlab™ imaging software.
Quantification of the bioluminescent signal
The bioluminescent signal was quantified by measuring the amount of highlighted pixels in the area shaped around each site of photon emission with the aid of the Openlab™ imaging software.
Detection of bone lesions by radiography
Radiographs of the mice, anaesthetized as described above for the BLI analysis, were taken using X-Omat TL films (Kodak, Lausanne, Switzerland).
Immunohistochemistry
The mice injected i.c. MDA-231-B/Luc+ cells were perfused, after sacrifice, with 60 ml of HBSS containing 20U heparin/ml and, then, with 100 ml of 4% paraformaldehyde in Dulbecco's PBS, pH 7.4. Bones that were shown by BLI to be site of bioluminescent emission were selectively excised and further fixed overnight by immersion in fixative at 4°C. After decalcification in EDTA they were processed for paraffin embedding.
Five µm serial sections, after re-hydration and endogenous peroxidase block, were digested for 20 minutes at 37°C with trypsin (0.1% in 25mM Tris, 140 mM NaCl and 10mM CaCl2) for antigen retrieval. Rabbit antibodies (10 μg/ml) against human pan-cytokeratin (Dako, Zug, Switzerland) or control normal rabbit IgG (Jackson ImmunoResearch, La
Roche, Switzerland) were followed by biotinylated swine anti-rabbit Ig antibodies (Dako) and streptavidin-biotinylated peroxidase complex (Amersham, Dubendorf, Switzerland).
The reaction was developed with 3-amino-9-ethyl-carbazole as chromogen. Sections were slightly counter-stained with hematoxylin. Size measurements of metastatic lesions were performed with the aid of an image analysis software (NIH Image; http://rsb.info.nih.gov/ nih-image).
Results
Monitoring in vivo development of metastases after intracardiac and intra-venous injection of cancer cells
In general, within 2 hours from the intracardiac injection of MDA-231-B/Luc+ cells 14 % of the mice died or showed signs of distress, for which they were subjected to euthanasia. The surviving mice all developed bone metastases, as detected by BLI. In contrast, none of the mice (n = 4) injected intra-venously showed either bone or soft tissue metastases during the entire period of observation (4 weeks), as detected both by BLI and radiography.
Ten minutes after i.c. injection of MDA-231-B/Luc+ cells, BLI showed diffuse photon accumulation over the entire animal body, with exclusion of the distal fore-and hind-legs, and of the tail (Fig. 1A) . Twenty-four hours later photon emission from the same animal was abolished (Fig. 1B) . However, after 4 weeks BLI could detect distinct areas of photon accumulation, suggestive of metastatic tumor growth, over the hind-legs and over the maxillofacial region of the same animal (Fig. 1C) .
First evidence of bioluminescent emission from bones, indicative of bone metastasis, was seen at day 24 after i.c. injection of cancer cells. In all mice (n = 4) discrete photon accumulation was localized over the distal metaphyses of the femurs ( Fig. 2A-D) and over the dorsal projection of the thoracic vertebrae (not shown). In one mouse photons accumulated also over the proximal metaphysis of the tibia (Fig. 2B) . Whole body radiographs taken at day 25 did not show any sign of osteolysis in any of the bones and, more specifically, in any of the bone locations that were origin of photon emission recorded the previous day (not shown).
The intensity of photon emission at the bone sites described above increased substantially from day 24 to day 33. Furthermore, at day 33, additional bone sites of bioluminescence became apparent (Fig. 3A-F) . At this time point, the average number of bone metastasis/ mouse attained to 6.33 (± 1.45, SEM). However, whole body radiographs taken at the same day showed bone lesions only in 1/3 of the bone sites revealed by photon detection (total 19 versus 6 bone sites, as detected by BLI and radiography, respectively; n mice = 3) (not shown). One animal survived until day 38 after i.c. injection of cancer cells. In this mouse an additional bioluminescent site appeared in the region of the sacral vertebrae (Fig. 4B) .
Meanwhile, the signal intensity over all the other bone sites further increased ( Fig. 4A-C) , as compared to day 33. However, the radiographic analysis of the bone lesions at day 38 did not reveal a modification in their number (Fig. 4D) , as compared to day 33. In all cases the bone lesions were characterized by subtle modifications of the metaphyseal spongiosa due to increased bone remodeling and/or limited areas of osteolysis (Fig. 4E,F) . At any time point, none of the animals of this series did show photon emission at extra-skeletal locations.
The quantification of the bioluminescent signal localized over the different bone metastatic sites from the time of their first appearance to the time of animal sacrifice ( Fig. 4G) allowed continuous monitoring in vivo of the growth kinetics for each single bone lesion.
Immunohistochemical analysis for human pan-cytokeratin expression confirmed the presence of cancer cells in all the bones that were shown by BLI to be site of bioluminescent emission. One bone metastatic growth was identified both by BLI and radiography as located in the proximal metaphysis of the humerus (Fig. 4A,D) . The histological and immunohistological analyses showed that cancer cells have extensively invaded the proximal half of the bone marrow cavity of this bone (Fig. 5A,C) . In contrast, small bone metastases were apparently located by BLI on the distal region of both tibiae (Fig. 3D,F 
Monitoring in vivo tumor growth after intraosseous implantation of cancer cells
Soon after implantation of 1x10 4 MDA-231-B/Luc+ cells into the tibia marrow cavity, no bioluminescent emission could be detected externally. However, already after 4 days there was a defined, although weak, photon emission localized over the area of implant. The signal on the same area increased progressively and became intense from day 14 (Fig. 6A) . Nevertheless, radiographs taken at equivalent time points (Fig. 6B) showed initial signs of osteolysis only at day 14. The osteolysis in the trabecular bone became clearly evident at day 25, and substantial erosion of the cortical bone was obvious at day 36.
The quantification at different time points of the bioluminescent signal localized over the site of implantation (Fig. 6C ) allowed continuous monitoring in vivo of tumor growth.
Determination of the lowest cell number detectable in bone by BLI respectively, clearly indicating that intensity of the signal detected by BLI is a function of the tissue composition and depth of the bioluminescent source. This is possibly due to light scattering and quenching by tissue components such as hemoglobin 16, 27 .
Polymerase chain reaction-(PCR-) based methods also allow sensitive detection and quantification of cancer cell burden in bone/bone marrow 20, 28, 29 . However, being methods ex vivo, they have severe limitations. First, in temporal studies several animal groups need to be sacrificed at different time points. Second, the bone sample is randomly selected and its size necessarily small and inevitably subject to sampling bias. Thus, large numbers of animals per group are needed to reach statistical significance. Third, these methods require disruption of the tissue samples. This precludes the possibility to perform parallel histology-based and gene expression analyses on the same bone sample. In contrast, BLI allows detailed anatomical information, continuous monitoring and precise quantification of bone metastatic growth in vivo, consistent reduction in the number of experimental animals and opportunity to perform end-point histological, immunohistological and gene expression analyses guided to the bone(s) specifically affected by metastatic disease.
A similar method of whole body reporter gene imaging able to visualize in vivo experimental metastases to bone and soft tissues has been reported 17 . This method utilizes GFP, instead of luciferase, as reporter gene. A possible concern regarding the use of GFP as reporter gene in whole body imaging is the auto-fluorescence generated in animal tissues by external light excitation 16, 17 . This background fluorescence may decrease the sensitivity of detection and, thus, delay early identification of bone metastatic foci. The GFP-based whole body imaging could visualize a bone metastatic lesion of about 0.96 mm in diameter at best 17 . At this tumor size the cancer cells may have already induced osteolytic and/or osteosclerotic lesions sufficient to be recognized by radiography. However, the sensitivity of GFP-reporter external imaging was not compared to radiography, and no histological proof of the presence and histomorphometric measurement of the size of the bone metastases were given 17 .
All carcinomas, both primary and secondary, when they reach the size of 2-3 mm 3 depend on angiogenesis for further growth 14, 15 . The ability of BLI to detect externally bone metastatic foci of even smaller size is extremely relevant in view of the necessity to investigate the pre-and peri-angiogenic phases of metastatic growth.
The model of i.c. injection of Luc-transfected cancer cells coupled to BLI detection and continuous monitoring in vivo of bone metastases will facilitate studies on the molecular mechanisms involved in early stages of metastatic disease (MRD) and the development of innovative therapeutic strategies.
